Account Navigation

Account Navigation

Currency - All prices are in AUD

Currency - All prices are in AUD
 Loading... Please wait...
Autism Coach

Fecal Transplants Become More Appetizing

Posted by on

Researchers have completed a pilot study that indicates that swallowing a capsule with with frozen or freeze dried fecal matter from a healthy person can help to eliminate Clostridia dfficile (C. diff) from the intestinal tract.  C. Diff is especially problematic and common in individual within the autism spectrum, producing the neurotoxin 4-Cresol, which is also implicated in psychosis.  Up until now, fecal transplants have been administered through a colonoscopy treatment which is more invasive and expensive.    This has huge implications for autism because most individuals within the autism spectrum have significant intestinal dysbiosis.  The possibility of easily establishing a more healthy microbiome could make a huge difference in the physical and mental health. Many of the toxins produced by a dysfunctional microbiome include excessive levels ammonia, oxalic acid and other neurotoxins that skew the basic metabolic processes that include the manufacture of antioxidants, neurotransmitters, and energy production throughout the body.

Fecal Microbiota Transplantation (TMP) is nearly as effective as fresh product in treating patients with Clostridium difficile (C-diff) infection, according to researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health and Kelsey Research Foundation. A new study, which proves that a pill form of treatment could be effective and more convenient for patients and physicians, was published in the most recent issue of Alimentary Pharmacology & Therapeutics.

For the study, UTHealth and Kelsey Research Foundation investigators enrolled 72 patients who had at least three bouts of recurrent C-diff in a clinical trial and treated them with either fresh, frozen or freeze-dried FMT product via colonoscopy. Fresh FMT product produced a 100 percent cure rate among participants; frozen product produced an 83 percent cure rate and freeze-dried product produced a 69 percent cure rate.

Frozen and fresh product fully restored the microbiota diversity among participants within seven days after treatment. Researchers saw some improvement in microbiota diversity among participants treated with freeze-dried product after seven days and full restoration of healthy bacteria within 30 days.

This is the first study to show that frozen and freeze-dried microbiota are as good as fresh material, so that we never have to use fresh again. It's a logistical nightmare to use fresh product. If we were going to treat you today, a donor would have come in two hours before, we would have already isolated the sample and then we would have to administer it the same day.

A pill form of the product could make all of this easier," said Herbert L. DuPont, M.D., senior author and director of the Center for Infectious Diseases at UTHealth School of Public Health.DuPont co-directs the FMT program with Zhi-Dong Jiang, M.D., Dr.P.H., associate professor in the Department of Epidemiology, Human Genetics and Environmental Sciences at the School of Public Health. DuPont is also the president and CEO of Kelsey Research Foundation."Freeze-dried product can be put into a pill that can be given orally, which is much more convenient for patients and physicians," said DuPont, who is currently testing the safety and efficacy of a pill version of the product.One of the participants in the clinical trial, John Siebert, was on vacation with his family in California when he contracted C-diff in August 2014. The 66-year-old, who is a professor of agricultural economics at Texas A&M University, sought medical care as soon as he returned to Texas but was stunned that his doctors did not know how to treat the condition in a lasting way. After four months and three bouts of C-diff that left him fighting for his life, Siebert was at a loss."It's extremely painful and debilitating because you can't ever really be far from a bathroom. I had really bad cramps and I ate a lot less because I didn't want to aggravate things," said Siebert, who lost nearly 20 pounds and missed a month of work.  Eventually, Siebert found DuPont and Jiang, who were enrolling patients in their FMT clinical trial. Siebert immediately signed up and had the procedure done in early December. Siebert felt mostly recovered by Christmas and was back to his normal self by March 2015.  It was a miracle! I love teaching and I can't tell you what it was like to be healthy again, to be able to do my job and not retire before I was ready," said Siebert.  Siebert's struggle to find a permanent cure to C-diff is not uncommon. Physicians typically treat C-diff with antibiotics, which can kill one form of the bacteria, the toxins. However, C-diff spores are much harder to kill and once the antibiotics have destroyed both good and bad bacteria in the gut, the remaining spores can release additional toxins. There is a 50 percent chance that a person who has C-diff will get a recurrent infection because of those toxins.

Story Source:

Materials provided by University of Texas Health Science Center at Houston

Journal Reference:

  1. Z. D. Jiang, N. J. Ajami, J. F. Petrosino, G. Jun, C. L. Hanis, M. Shah, L. Hochman, V. Ankoma-Sey, A. W. DuPont, M. C. Wong, A. Alexander, S. Ke, H. L. DuPont. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Alimentary Pharmacology & Therapeutics, 2017; 45 (7): 899 DOI: 10.1111/apt.13969
  • clostridia therapy
  • get rid of clostridia
  • fecal transplants
  • oral fecal transplant
comments powered by Disqus